Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07630363CT.gov PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | — | Not Yet Recruiting | — | — | — |
NCT07469683CT.gov An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT05949632CT.gov A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05097599CT.gov StrataPATH™ (Precision Indications for Approved Therapies) | — | Terminated | — | — | — |
NCT05059522CT.gov Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | — | Active Not Recruiting | — | — | — |
NCT04385654CT.gov Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma | — | Unknown | — | — | — |
NCT03297606CT.gov Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | — | Recruiting | — | — | — |
NCT01999972CT.gov A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01540526CT.gov Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib | — | Completed | — | — | — |
NCT01744249CT.gov Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | — | Completed | — | — | — |
Show 3 more trialsShow fewer
NCT01529138CT.gov Study of Axitinib and Temsirolimus in Solid Tumors | — | Completed | — | — | — |
NCT00949624CT.gov CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors | — | Completed | — | — | — |
NCT01469052CT.gov First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Axitinib (this asset) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | B · 60 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Axitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Kidney Neoplasm | — | P3 | BB · 69 |
| Renal Cell Carcinoma | — | P4 | BB · 67 |
| Kidney Cancer | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Axitinib in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/axitinib-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →